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Abstract
Purpose: Hormone treatment in trans women in Europe usually consists of the administration of estrogens and
antiandrogens, for example, cyproterone acetate (CPA). Mild serum prolactin elevations during follow-up are
attributed to estrogen therapy. This analysis evaluates whether CPA contributes to the elevation of prolactin
in trans women receiving gender affirming hormones.
Methods: This study is part of the endocrine part of the European Network for the Investigation of Gender Incon-
gruence (ENIGI). Belgian data were selected for this substudy. Trans women who initiated gender affirming hor-
mone treatment and underwent orchiectomy were prospectively evaluated. Trans women were treated with oral
CPA 50mg in combination with estrogen substitution. Postsurgery, estrogen was reinitiated in an unchanged
dose. Sex steroids, gonadotropins, and prolactin were compared at baseline, pre- and postsurgery in patients re-
ceiving orchiectomy, and at baseline, 12, and 18 months in patients who did not undergo orchiectomy.
Results: One hundred and seven trans women participated in this analysis, with a mean age of 31.5 years. An
increase in serum prolactin levels was seen in the group undergoing orchiectomy (23.72lg/L) and not undergo-
ing orchiectomy (23.05lg/L) at the preoperative and 12-month visit, compared with baseline (9.42 lg/L,
P = 0.002 and 9.94lg/L, P < 0.001, respectively). After orchiectomy, a decline in prolactin levels (10.17lg/L,
P < 0.001) occurred.
Conclusions: CPA is likely to cause a temporary increase in serum prolactin, with prolactin levels returning to
normal after orchiectomy and CPA discontinuation.
Keywords: clinical care, clinical research, gender dysphoria, gender identity, gender transition, transgender
Introduction
The transgender population that is actively seekingendocrine treatment is increasing.1 However, trans-
gender care is not a strong part of the medical curriculum
and many physicians might not know how to interpret cer-
tain test results.2 The current treatment regimens for trans
women in Europe usually involve hormone therapy as
well as gender affirming surgery. Hormone treatment in
Europe generally consists of estrogens (estradiol valerate)
and antiandrogens (cyproterone acetate, CPA).3 In trans
women, the use of an antiandrogen agent is necessary to
suppress testosterone levels and decrease masculine sec-
ondary sexual characteristics, until orchiectomy has been
performed. The World Professional Association for Trans-
gender Health (WPATH) Standards of Care4 requires at
least 1 year of gender affirming hormonal therapy before
orchiectomy can be performed, although exceptions are
allowed in the case of medical contraindications or other
compelling reasons. CPA is an androgen receptor antago-
nist that is a synthetic derivative of 17-OH progesterone.
CPA reduces serum testosterone levels by acting as a direct
antagonist on the peripheral androgen receptor and by its
progestational and weak glucocorticoid activity that inhib-
its luteinizing hormone (LH) release.5
In the literature, elevations in serum prolactin levels are
reported in up to 20% of trans women treated with estrogens
and are sometimes associated with enlargement of the
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pituitary gland.6,7 Previously, this prolactin elevation was
thought to be caused only by an estrogen-mediated decreased
effectiveness of dopamine-mediated inhibition of prolactin
secretion from the pituitary gland.8,9 Articles concluding
that not only estrogens but also CPA therapy may lead to
an increase in serum prolactin levels are scarce10,11 and pro-
spective data are not available.
There have been case reports of prolactinomas occurring
after long-term or high-dose estrogen therapy;12–16 however,
these findings were not reported in large cohorts of estrogen-
treated transgender persons. As high levels of estrogen are
known to enlarge the pituitary gland, physicians may fear
prolonged high doses of estrogen causing prolactinomas in
transgender persons. Therefore, the Clinical Practice guide-
lines of the Endocrine Society for the endocrine treatment
of transgender persons recommend monitoring serum prolac-
tin levels at baseline and then at least annually during the
transition period and biannually thereafter,7 whereas the
Endocrine Society Clinical Practice Guidelines on pitui-
tary incidentaloma17 do not suggest assessing serum prolac-
tin levels routinely.
Another common cause of drug-induced elevated serum
prolactin is the use of certain antidepressive and antipsy-
chotic agents. Mental health issues are frequently observed
in transgender persons, and studies report that transgender
adults are burdened by mental health concerns, including
mood disorders, suicidal and nonsuicidal self-injury, and
anxiety disorders.18 There is a marked decrease in psycho-
neurotic distress (including anxiety, depression, interper-
sonal sensitivity, and hostility) after the initiation of gender
affirming hormone therapy.19
Prolonged elevated prolactin levels can induce erectile
dysfunction in men and loss of sexual desire in both
sexes.20 In cisgender women, hyperprolactinemia is usually
reflected on the gonadotroph axis (hypogonadotropic hypo-
gonadism), with alterations in gonadotropin-releasing hor-
mone (GnRH) pulsatility, decreased levels of estradiol, and
menstrual abnormalities. In trans women, these effects are
not described because of the anatomical situation or the con-
current hormone treatment.21 High levels of prolactin can
cause galactorrhea, which is reported in 9%–14% of trans
women receiving estrogen therapy.22 However, the galactor-
rhea seen in trans women is usually very mild and transient.23
In this article, we wanted to verify whether CPA contrib-
utes to the elevation of prolactin in trans women receiving
gender affirming hormones or if this effect can be attributed
to the administration of estrogens. We also aimed to assess
the clinical relevance of the observed elevation in serum
prolactin levels.
Methods
This research is part of the ‘‘European Network for the
Investigation of Gender Incongruence’’ (ENIGI), a collabo-
ration of four major West European gender identity clinics
(Amsterdam, Ghent, Florence, and Oslo), a study group cre-
ated to obtain more transparency in diagnostics and treat-
ment of gender dysphoria.
From February 15, 2010 to August 23, 2016, 187 trans
women were included in the ENIGI study at the Ghent Uni-
versity Hospital in Belgium. All patients were 16 years old
or older and underwent a standardized diagnostic procedure
to confirm the diagnosis of gender incongruence/gender
dysphoria before initiating treatment.3 Patients were in-
cluded in the ENIGI endocrine protocol when they started
medical treatment for gender incongruence. Every patient
was treated in accordance with the WPATH Standards of
Care, Version 7.4 Exclusion criteria were previous use of
gender affirming hormones, insufficient knowledge of the
native languages (Dutch or French), use of medication
known to induce elevations of serum prolactin, and preex-
isting conditions known to cause hyperprolactinemia.24 At
the start of the study, patients received oral and written in-
formation about the ENIGI endocrine protocol by the phy-
sician. Written informed consent was obtained according to
the Ethics Committee of the Ghent University Hospital,
which approved all aspects of the study.
To analyze if a prolactin elevation occurred in trans
women, we chose to include only those who had at least 1
year of follow-up, which resulted in 153 cases. The complete
study protocol of the endocrine part of the ENIGI study can
be found in Dekker et al.3 The short-term follow-up currently
consists of a visit at baseline and after 3, 6, 9, 12, 18, 24, and
36 months of gender affirming hormone therapy.
In trans women, the hormone treatment consists of CPA
50mg in one daily dose, usually in combination with an oral
estradiol agent, estradiol valerate (Progynova, Bayer, Ger-
many) 2mg twice daily. In patients older than 45 years of
age, estradiol was administered transdermally in the form of
estradiol patches (Dermestril, Besins, Belgium) in a dose
of 100lg/24 hours, to avoid the increased risk for thrombosis
from oral estrogens caused by the first pass effect of the liver.
In case of nontolerance, 1.5mg of transdermal 17-b E2 gel
twice daily (Oestrogel, Besins) was given. After orchiec-
tomy, estrogen alone is continued in an unchanged dose.
At baseline and during each follow-up visit, standard clin-
ical measurements are assessed, including body weight and
height, which is further detailed in Dekker et al.3 Routine
questioning on the occurrence of galactorrhea was included.
These clinical measures are filled out on a standardized form.
Upon each visit, venous blood samples are obtained after
overnight fasting. Competitive chemiluminescent immuno-
assays were run for estradiol (E170 Modular, Roche; LOQ
25 pg/mL), prolactin (IMMULITE 2000XPi, Siemens;
LOQ 0.5 ng/mL), serum testosterone (E170 Modular,
Roche; LOQ 10 ng/dL), LH (E170 Modular, Roche; LOQ
0.1mIU/mL), follicle-stimulating hormone (FSH) (E170
Modular, Roche; LOQ 0.1mIU/mL), and sex hormone-
binding globulin (SHBG) (E170 Modular, Roche; LOQ
0.35 nM). The free testosterone concentration was calculated
from the total serum hormone concentration, serum SHBG,
and serum albumin, using a validated equation derived
from the mass action law. Tests for excluding macroprolac-
tinemia (estimating the monomeric component after protein
precipitation with polyethylene glycol) were performed in
patients with prolactin levels >50 ng/mL. There were no pa-
tients with elevated prolactin levels due to macroprolactinemia.
We chose to analyze whether prolactin differed in patients
undergoing orchiectomy (group A) versus patients not under-
going orchiectomy (group B). We decided to compare these
two groups at different times. We compared the patients’
prolactin at their first visit (M0), at their last visit preopera-
tively (group A) versus 12-month checkup (group B) and at
the first postoperative visit (group A) versus 18-month
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checkup (group B). We chose the 12 and 18 months visits
because these correlated best with the last preoperative
and first postoperative visit, respectively, as the mean
time between initiation of therapy and orchiectomy was
17.5 months.
It has been described that serum prolactin can be corre-
lated with body mass index (BMI) and/or age.25 Because
our patients’ serum prolactin levels did not correlate to
their BMI and age, we did not control for these parameters.
Reference ranges for prolactin are 1–17 lg/L in cisgender
men and 6–30lg/L in cisgender women. In our laboratory,
reference ranges for prolactin are shown according to one’s
legal sex, which can only be changed after gonadectomy.
Hyperprolactinemia is defined as an elevated prolactin,
above the reference ranges for one’s sex. However, to the
knowledge of the authors of this article, there are currently
no reference ranges for prolactin levels in trans women.26
Therefore, we decided to use cisgender male reference
ranges for prolactin at the first visit and cisgender female ref-
erence ranges for prolactin after initiation of hormone ther-
apy to define hyperprolactinemia.
Data were analyzed using IBM SPSS 23.0 software (IBM
Corporation, Armonk, New York) and were verified for nor-
mal distribution using the Shapiro–Wilk test. Patients were
divided into two groups: those who underwent orchiectomy
(group A) and those who did not (yet) undergo orchiectomy
(group B). Differences between groups were analyzed using
unpaired t-tests (for normally distributed data) and Mann–
Whitney U tests (for nonnormally distributed data). To evaluate
prolactin differences over time, we performed one-way
ANOVA with repeated measurements in case of normally
distributed data; for nonnormally distributed data, we per-
formed Friedman tests with post hoc analysis by means of
Wilcoxon signed-rank tests with an applied Bonferroni cor-
rection.
Results
One hundred and fifty-three trans women had 1 year of
follow-up (Fig. 1). Reasons for not including study patients
in this analysis were dropout/lost to follow-up (N= 33), use
of medication known to induce elevation in serum prolactin
levels (N = 10; 8 because of selective serotonin reuptake in-
hibitors (SSRIs), 2 because of antihistamines), current condi-
tions known to elevate serum prolactin levels (N = 0), and
patients in whom prolactin was not assessed during at least
three visits (N=3). This resulted in 107 test cases. The mean
age of participants in our study population was 31.5 years old
with a mean BMI of 23.2 kg/m2, which was not different be-
tween groups undergoing versus not undergoing orchiectomy.
Regarding hormone status at baseline, our two groups were
also quite similar (Table 1).
None of the trans women in our study population was di-
agnosed with prolactinoma during the investigated time pe-
riod. None of our patients reported galactorrhea. During
the investigated time period, 58 (54.2%) trans women under-
went orchiectomy (group A), whereas 49 (45.8%) did not
(yet) undergo orchiectomy (group B). Orchiectomy gener-
ally took place after 17.5 months, and at the same time,
CPA was interrupted. After initiation of hormone therapy,
we noticed an increase in serum estrogen levels and a de-
crease in serum testosterone and free testosterone levels
FIG. 1. Flowchart of the study population.
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upon the second visit in both groups. We also noticed a sup-
pression of serum LH and FSH levels after initiation of ther-
apy. In group A, there was an increase in serum LH and FSH
after orchiectomy and discontinuation of CPA therapy
(Fig. 2).
We noticed higher levels of serum estrogen in groups with
transdermal estrogen application, compared with groups on
oral administration of estrogens (P< 0.001 for preopera-
tive values, P = 0.003 postorchiectomy, P= 0.028 at month
12 [M12], and P< 0.001 at month 18 [M18]) (data not
shown). There was no difference in the serum estradiol values
before and after orchiectomy or between the 12- and 18-month
visits. However, we did notice a difference in the serum LH
and FSH levels before and after orchiectomy, whereas there
was no difference in the group not undergoing orchiectomy.
In the study population, mean serum prolactin at baseline
was 9.65– 9.21lg/L, and this was similar among both groups
(Table 1).
Seven patients (6.6%) had an elevated prolactin at base-
line, with a maximum reported value of 72.40lg/L. In all
of these patients, this elevation of serum prolactin at baseline
decreased after their first visit. We noticed an increase in
serum prolactin after 12 months of hormone therapy and at
the preoperative visit in both groups, compared with baseline
(P < 0.001 and P = 0.002, respectively), (as shown in Fig. 3
and Table 2). We assessed whether prolactin levels were dif-
ferent in group A versus group B at different times. After
orchiectomy and discontinuation of CPA, we noticed a return
to baseline OF prolactin levels (P < 0.001), whereas we also
described a decline in serum prolactin levels in group B
(P < 0.001), although the decline was not as severe as in
group A.
At baseline and preorchiectomy and at the 12-month visit,
we found no difference in serum prolactin levels in group A
versus group B, whereas the postoperative serum prolactin
levels (group A) were lower than the 18-month serum prolac-
tin levels (group B) (P= 0.008) (Table 3). In addition, we ob-
served a positive relationship between serum estradiol levels
and serum prolactin levels after 12 months of gender affirm-
ing hormone therapy and preorchiectomy (Spearman’s rho
0.348, P< 0.001). After orchiectomy and after 18 months of
gender affirming hormone therapy, we no longer found a cor-
relation between serum estradiol levels and serum prolactin
levels.
Discussion
In this prospective analysis, we assessed whether mild
elevated serum prolactin in trans women is associated with
use of CPA. We described a decline in serum prolactin in
the first postoperative laboratory analysis in the group of
trans women undergoing orchiectomy. We suggest that this
is caused by stopping the CPA, unrelated to the administra-
tion of estrogens, as estrogens are continued with an un-
changed dose after orchiectomy and the estradiol levels are
not significantly lower.
The mechanism behind the CPA- induced increase in
serum prolactin is not well understood. One suggested mech-
anism is drug-induced secondary hypogonadism, with CPA
suppressing the pulsatile GnRH release, resulting in low
LH and FSH levels, which may lead to elevated serum pro-
lactin levels.27 Other articles reporting progesterone-induced
hyperprolactinemia are scarce28,29 and also support the hy-
pothesis of a progesterone-mediated suppressing of the GnRH
release, in addition to a progesterone-induced reduction of
hypothalamic dopamine. However, these articles do not spec-
ify which type of progesterone caused the documented eleva-
tion in serum prolactin levels.
Table 1. Baseline Characteristics of the Study Population
Total Group A Group B P-value
Baseline characteristics
Number of cases (%) 107 (100%) 58 (54.2%) 49 (45.8%)
Age (years) 31.48 – 12.35 32.35– 12.83 30.75 – 11.95 0.444
Weight (kg) 73.42 – 14.80 72.26– 12.43 73.72 – 17.21 0.808
Height (m) 1.779 [1.732–1.823] 1.773 [1.720–1.819] 1.791 [1.751–1.827] 0.579
BMI (kg/m2) 23.22 – 4.55 23.26– 3.70 23.12 – 5.38 0.669
Type of estrogen therapy
Oral 71 (66.4%) 37 (63.8%) 34 (69.3%) 0.352
Transdermal 26 (24.3%) 17 (29.3%) 9 (18.3%) 0.424
Baseline laboratory
Prolactin (lg/L) 9.65 – 9.21 9.42 – 8.64 9.94 – 9.94 0.785
LH (U/L) 4.85 – 2.13 4.78 – 2.19 4.87 – 2.09 0.599
FSH (U/L) 4.48 – 4.17 4.86 – 4.50 4.12 – 3.84 0.930
E2 (ng/L) 29.91 – 11.80 30.35– 9.71 29.37 – 13.87 0.853
SHBG (ng/dL) 38.85 – 18.15 39.65– 16.27 38.31 – 20.17 0.509
Testosterone (ng/dL) 501.25 [390.03–625.93] 543.30 [417.60–629.70] 475.30 [363.05–617.13] 0.137
FT (ng/dL) 10.2 [8.51–12.00] 10.30 [8.56–12.00] 10.05 [8.05–11.45] 0.282
Group A is defined as patients undergoing orchiectomy, group B is defined as patients not undergoing orchiectomy. Tests for normality
were performed by Shapiro–Wilk. For normally distributed values, mean values – standard deviations are shown. For values that are not nor-
mally distributed, median values and IQR [P25 and P75] are shown, unless otherwise specified. For normally distributed values, unpaired
Student’s t test was used to quantify differences between both groups. For nonparametric values, the Mann–Whitney U test was performed,
and for categorical variables, we used the Chi-square test.
LH, luteinizing hormone; FSH, follicle-stimulating hormone; E2, estradiol; SHBG, sex hormone-binding globulin; FT, free testosterone.
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We also described low serum LH and FSH levels after ini-
tiation of hormone therapy, which increased again after
orchiectomy, whereas there was no increase in the trans
women who did not undergo orchiectomy. As all patients
were treated with the same dosage of estrogens (which is
supraphysiological in menopausal women), we hypothesize
that the lack of free testosterone may be a causal factor for
the higher LH and FSH levels, when these are no longer sup-
pressed by CPA. We hypothesize that estrogens cannot (suf-
ficiently) suppress LH and FSH levels in trans women. The
groups presented in this study are too small to test this hy-
pothesis at this point and further research may be needed.
As other studies suggest, an elevation in prolactin levels
during estrogen treatment may occur. Asscheman et al.6 fol-
lowed 214 trans women treated with ethinyl estradiol
(100 lg/day) and CPA (100mg/day). They documented
an elevated serum prolactin above normal in all subjects
(>30lg/L), which decreased by more than 50% spontane-
ously or after dose reduction of oral estrogens. In addition,
they observed a higher incidence of prolactin levels greater
than 1000mU/L in trans women with high doses of estrogens
and advanced age at the start of treatment. Therefore, they
concluded that estrogen administration in trans women
causes elevations in serum prolactin levels. Gooren et al.30
followed 142 trans women, treated with CPA 100mg/day.
After 3 months, ethinyl estradiol 100lg/day was added to
the treatment. They observed a rise in serum prolactin levels
during the first 15 months of hormone treatment, which was
already apparent after 3 months of therapy with CPA alone,
but increased further after adding ethinyl estradiol 100lg/day.
In our study population, we noticed higher serum estrogen
levels in patients treated with transdermal estrogens com-
pared with those taking oral estrogen therapy, which did
not result in higher levels of serum prolactin. We described
a decline in serum prolactin levels in trans women who un-
derwent orchiectomy and stopped CPA, whereas in the
FIG. 2. Effects of hormone therapy in trans women. Figure 2 shows the evolution of serum luteinizing hormone (LH),
follicle-stimulating hormone (FSH), estrogen (E2), and testosterone levels in time in trans women undergoing versus not un-
dergoing orchiectomy during the first visit (1), preoperative or at the 12-month visit (Preop/M12) (2) and postoperative or
after 18 months (Postop/M18) (3). The symbol * indicates a significant difference (P < 0.05) between the first and second
visit,  indicates a significant difference (P< 0.05) between the first and third visit.
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trans women who were receiving hormone treatment but did
not undergo orchiectomy, the increase in serum prolactin
levels induced by hormone therapy persisted. After orchiec-
tomy, antiandrogens were stopped in our study protocol,
whereas trans women not undergoing orchiectomy continued
both estrogens and antiandrogens. Therefore, we conclude
that the elevated prolactin in our trans women (N = 19,
17.8%) could be attributed to the administration of CPA,
rather than the estrogen treatment.
These findings have previously been documented by Sofer
et al.,10 Nota et al.,11 and Gava et al.31 Sofer et al.10 described
124 trans women who were followed for 18 months. Estro-
gen treatment was titrated to achieve estradiol levels in
the normal premenopausal range. Antiandrogenic treat-
ment consisted of GnRH-analogs (10.2%), CPA (70%),
or spironolactone (17.6%). They noticed an increase in
prolactin levels compared with baseline, which was al-
ready apparent 3 months after initiation of CPA treatment.
By 18 months, the mean increase in serum prolactin levels
in the group receiving CPA treatment was greater than the
increase in serum prolactin levels in the group taking spi-
ronolactone. They observed no increase in serum prolactin
levels in patients treated with GnRH-analogs, but the num-
ber of patients in this group was too small for analysis.
Gava et al.31 followed 40 trans women for 1 year. Twenty
trans women were treated with CPA 50mg daily and trans-
dermal estradiol 1mg or 2mg daily, whereas the other
twenty trans women received leuprolide acetate 3.75mg
FIG. 3. Serum prolactin levels in trans women with or
without orchiectomy. Boxplots for the evolution of prolactin
levels (mean – SD) in time in trans women with (group A)
versus without (group B) orchiectomy during the first visit
(1), preoperative or at the 12 month visit (2) and postopera-
tive or after 18 months (3). The symbol * indicates a signif-
icant difference (P< 0.05) between the first and second visit,
 indicates a significant difference (P < 0.05) between the
second and third visit.
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(a GnRH-analog) intramuscularly, monthly, with the same
estrogen dose. After 1 year, they observed an increase in
serum prolactin levels (compared with baseline) in the
group receiving CPA, whereas there was no difference in
serum prolactin levels in the group treated with leuprolide
acetate. These findings also suggest that the observed eleva-
tion in serum prolactin levels in trans women can be attrib-
uted to the CPA treatment.
In three case reports describing trans women with prolac-
tinoma, estrogen doses were not controlled by a physi-
cian, with patients surpassing the maximum doses.6,14,15
However, some case reports do mention patients adhering
to adequate hormone doses presenting with hyperpro-
lactinemia.12,13,16 These patients presented with symptoms
suggestive of hyperprolactinemia, including mastodynia,
hemicranial migraine, headaches, asthenia, galactorrhea
double vision, right-sided third nerve palsy, and generalized
weight gain. Magnetic resonance imaging (MRI) revealed
a macroprolactinoma. Bunck et al.13 reported one asymp-
tomatic patient adhering to adequate hormone doses,
whose serum prolactin levels increased after 15 years of
hormone therapy (CPA 50mg twice a day plus ethinyl es-
tradiol 50 lg twice a day), with a 8mm diameter focal
hypointense lesion of the pituitary gland on MRI. There-
fore, we suggest that hormone therapy in trans women is
safe and does not induce prolactinoma if the patient adheres
to the prescription dose.
During the first visit with the endocrinologist, there might
be an elevation in serum prolactin levels, which was the case
in 7.3% of our participants at one point during the investi-
gated time period. This elevation is probably caused by the
stress of starting the transitioning process and experiencing
the new medical environment. Therefore, it is not clinically
relevant. As the CPA-induced elevation in serum prolactin
is only moderate without clinical implications in our study
population, we advise against measuring serum prolactin lev-
els at baseline and serially, in contrast with the Endocrine
Society Clinical Practice Guidelines on the endocrine treat-
ment of transgender persons, which suggest monitoring at
baseline and annually.7 However, if the patient presents
with symptoms (headache, blurry vision, galactorrhea, etc.)
or biochemical signs (e.g., baseline low serum testosterone)
suggestive of prolactinoma, further diagnostic steps should
be taken; serum prolactin should be assessed and a brain
MRI scan can be planned.
As for the strengths of this study, this is the first prospec-
tive analysis, to the knowledge of the authors of this article,
that suggests that CPA can induce elevated serum prolactin,
as the only published article mentioning CPA-induced ele-
vated serum prolactin levels in trans women was a retrospec-
tive analysis.11 In this study, we excluded patients using
certain medications known to induce elevations in serum
prolactin levels and all of our patients underwent the same
hormone treatment, with the only variation being the admin-
istration mode of the estrogens. Patients’ variables were
measured during standardized visits.
Some limitations of this study should be considered. As
CPA is not currently approved by the Food and Drug Admin-
istration in the United States, the results of this analysis
cannot be extrapolated to the entire transgender popula-
tion receiving antitestosterone treatment. Other antiandro-
gen agents (e.g., spironolactone or GnRH-analogs) have
T
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not been included in this analysis. In addition, we were not
able to perform multivariate analyses, as our data did not
match all assumptions to proceed with multivariate analyses.
Conclusion
It is important to know how to interpret certain laboratory
results in transgender persons seeking physician-controlled
hormone therapy. The endocrinologist should be aware that
CPA can induce mild serum prolactin elevations in trans
women. However, as long as this elevation is mild and the
patient does not present with symptoms suggestive of hyper-
prolactinemia, we suggest that further diagnostic actions are
not needed. It is our opinion that our findings may lead to an
improvement in the follow-up of trans women taking CPA.
Unless the patient presents symptoms or biochemical
signs suggestive of prolactinoma, serially monitoring
serum prolactin levels is not necessary in trans women, as
the observed increase in serum prolactin levels in trans
women is transient and not clinically relevant. Not annually
assessing serum prolactin levels may cause less concerns
and stress in both patients and hormone prescribing physi-
cians. In addition, it may lead to less laboratory and techni-
cal imaging costs.
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